Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 28;27(40):6775-6793.
doi: 10.3748/wjg.v27.i40.6775.

Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer

Lorena Ostios-Garcia  1 , Julia Villamayor  1 , Esther Garcia-Lorenzo  1 , David Vinal  1 , Jaime Feliu  2
Affiliations
Review

Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer

Lorena Ostios-Garcia et al. World J Gastroenterol. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor with high lethality. Even with surgery, radiotherapy, chemotherapy, and other locoregional or systemic therapies, the survival rates for PDAC are low and have not significantly changed in the past decades. The special characteristics of the PDAC's microenvironment and its complex immune escape mechanism need to be considered when designing novel therapeutic approaches in this disease. PDAC is characterized by chronic inflammation with a high rate of tumor-associated macrophages and myeloid-derived suppressor cells and a low rate of natural killer and effector T cells. The pancreatic microenvironment is a fibrotic, microvascularized stroma that isolates the tumor from systemic vascularization. Immunotherapy, a novel approach that has demonstrated effectiveness in certain solid tumors, has failed to show any practice-changing results in pancreatic cancer, with the exception of PDACs with mismatch repair deficiency and high tumor mutational burden, which show prolonged survival rates with immunotherapy. Currently, numerous clinical trials are attempting to assess the efficacy of immunotherapeutic strategies in PDAC, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell transfer, alone or in combination with other immunotherapeutic agents, chemoradiotherapy, and other targeted therapies. A deep understanding of the immune response will help in the development of new therapeutic strategies leading to improved clinical outcomes for patients with PDAC.

Keywords: Cancer vaccines; Immune evasion; Immunity; Immunotherapy; Pancreatic cancer; Tumor microenvironment.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: Authors declare no conflict of interest for this manuscript.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med . 2013;369:1691–1703. - PMC - PubMed
    1. Young K, Hughes DJ, Cunningham D, Starling N. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Ther Adv Med Oncol . 2018;10:1758835918816281. - PMC - PubMed
    1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol . 2016;22:9694–9705. - PMC - PubMed
    1. Seufferlein T, Bachet JB, Van Cutsem E, Rougier P ESMO Guidelines Working Group. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol . 2012;23 Suppl 7:vii33–vii40. - PubMed
    1. Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer . 2012;118:2674–2681. - PMC - PubMed